...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life
【24h】

The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life

机译：益生菌和花生口服免疫疗法对健康相关质量的纵向影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double‐blind, placebo‐controlled randomized trial. This study evaluated the impact of PPOIT on health‐related quality of life (HRQL). Method Fifty‐one participants (PPOIT 24; placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ‐PF) and Food Allergy Independent Measure (FAIM) at pre‐treatment, end‐of‐treatment and 3?months after end‐of‐treatment. A total of 42 participants (20 PPOIT; 22 placebo) completed measures at 12?months post‐treatment. Changes over time in PPOIT and placebo groups were examined by repeated‐measures analysis of variance and paired t tests. Results Probiotic and peanut oral immunotherapy was associated with significant improvement in FAQLQ‐PF ( F ?=?3.63, P ?=?.02), with mean difference 0.8 at 3?months post‐treatment ( P ?=?.05) and 1.3 at 12?months post‐treatment ( P ?=?.005), exceeding the 0.5 minimal clinically important difference for FAQLQ‐PF. For FAIM, mean difference was 0.5 ( P ?=?.03) at 3?months and 0.4 ( P ?=?.04) at 12?months post‐treatment. In placebo group, post‐treatment FAQLQ and FAIM remained unchanged from pretreatment. Improvement in FAQLQ‐PF and FAIM scores related specifically to acquisition of sustained unresponsiveness rather than to receiving PPOIT treatment or participation in the trial. Conclusions Probiotic and peanut oral immunotherapy has a sustained beneficial effect on psychosocial impact of food allergy at 3 and 12?months after end‐of‐treatment. Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological well‐being was not negatively impacted. Improved HRQL was specifically associated with acquisition of sustained unresponsiveness.
机译：摘要背景我们之前报道了益生菌和花生口服免疫疗法（PPOIT）在双盲，安慰剂对照试验中与安慰剂相比诱导持续的反应性。本研究评估了PPOIT对与健康相关生活质量（HRQL）的影响。方法五十一位参与者（PPOIT 24;安慰剂27）从PPOIT试验完成食物过敏的生活质量问卷（FAQLQ-PF）和食品过敏的独立措施（FAIM）在预处理，治疗结束和3个月治疗结束后。共有42名参与者（20个PPOIT; 22 Placebo）在治疗后12个月完成措施。通过重复措施的差异分析和配对T检验来检查PPOIT和安慰剂组随时间的变化。结果益生菌和花生口服免疫疗法与FaqlQ-PF（F？= 3.63，P？=β.02）的显着改善有关，平均差异为0.8在治疗后3个月（P？= 05）和1.3在12？月后治疗（P？= 005），超过FAQLQ-PF的0.5个小临床重要差异。对于Faim，平均差异为0.5（p？=β.03），3个月和0.4（p？=Δ.04）在治疗后12个月。在安慰剂组中，治疗后FAQLQ和FAIM从预处理中保持不变。 FaqlQ-PF和FAIM分数的改进，特别是收购持续的无反应性，而不是接受PPOIT治疗或参与审判。结论益生菌和花生口腔免疫疗法对食物过敏的心理社会影响在3和12月3日持续有益效果，治疗结束后数月。治疗与PPOIT或安慰剂组中相对于基线的降低的HRQL无关，表明PPOIT耐受良好，心理福祉没有受到负面影响。改进的HRQL与获取持续的反应性有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号